Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IFN-gamma positive selected T-cells (University Hospital, Basel)
- Development stage
- Phase 2
- Lead developer
- University Hospital Basel
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Tumor-Infiltrating Lymphocytes (TILs) → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
IFN-gamma positive selected T-cells are an investigational adoptive cellular therapy developed by the University Hospital, Basel. This therapy involves the isolation of virus-specific T-cells (VSTs) from a hematopoietic stem cell transplantation (HSCT) donor using the CliniMACS Cytokine Capture System (CCS). The process identifies and selects T-cells that secrete interferon-gamma (IFN-γ) upon stimulation with specific viral antigens from Adenovirus (AdV), Epstein-Barr virus (EBV), and Cytomegalovirus (CMV). These selected cells are then infused into the HSCT recipient to restore cellular immunity and treat refractory post-transplant viral infections. This approach aims to provide rapid, targeted antiviral activity while minimizing the risk of graft-versus-host disease (GvHD) by depleting non-specific alloreactive T-cells.
- Other names
- Donor-derived virus-specific T-cellsCCS-selected T-cellsIFN-gamma positive selected T-cellsVirus-specific T-cells (University Hospital, Basel)
Beyond the preview
Go deeper on IFN-gamma positive selected T-cells (University Hospital, Basel).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IFN-gamma positive selected T-cells (University Hospital, Basel).